162 related articles for article (PubMed ID: 33749384)
21. Histologic features and prognosis in pediatric medulloblastoma.
Verma S; Tavaré CJ; Gilles FH
Pediatr Dev Pathol; 2008; 11(5):337-43. PubMed ID: 18201118
[TBL] [Abstract][Full Text] [Related]
22. DNA methylation profiling is a method of choice for molecular verification of pediatric WNT-activated medulloblastomas.
Korshunov A; Sahm F; Zheludkova O; Golanov A; Stichel D; Schrimpf D; Ryzhova M; Potapov A; Habel A; Meyer J; Lichter P; Jones DTW; von Deimling A; Pfister SM; Kool M
Neuro Oncol; 2019 Feb; 21(2):214-221. PubMed ID: 30252101
[TBL] [Abstract][Full Text] [Related]
23. Approach to molecular subgrouping of medulloblastomas: Comparison of NanoString nCounter assay versus combination of immunohistochemistry and fluorescence in-situ hybridization in resource constrained centres.
Kaur K; Jha P; Pathak P; Suri V; Sharma MC; Garg A; Suri A; Sarkar C
J Neurooncol; 2019 Jul; 143(3):393-403. PubMed ID: 31104222
[TBL] [Abstract][Full Text] [Related]
24. Desmoplastic/nodular medulloblastomas (DNMB) and medulloblastomas with extensive nodularity (MBEN) disclose similar epigenetic signatures but different transcriptional profiles.
Korshunov A; Sahm F; Okonechnikov K; Ryzhova M; Stichel D; Schrimpf D; Casalini B; Sievers P; Meyer J; Zheludkova O; Golanov A; Lichter P; Jones DTW; Pfister SM; Kool M; von Deimling A
Acta Neuropathol; 2019 Jun; 137(6):1003-1015. PubMed ID: 30826918
[TBL] [Abstract][Full Text] [Related]
25. Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study.
Eberhart CG; Kepner JL; Goldthwaite PT; Kun LE; Duffner PK; Friedman HS; Strother DR; Burger PC
Cancer; 2002 Jan; 94(2):552-60. PubMed ID: 11900240
[TBL] [Abstract][Full Text] [Related]
26. CTGF expression is indicative of better survival rates in patients with medulloblastoma.
Cruzeiro GAV; Lira RCP; de Almeida Magalhães T; Scrideli CA; Valera ET; Baumgartner M; Tone LG
Cancer Gene Ther; 2020 May; 27(5):378-382. PubMed ID: 31073205
[TBL] [Abstract][Full Text] [Related]
27. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma.
Rodriguez-Blanco J; Pednekar L; Penas C; Li B; Martin V; Long J; Lee E; Weiss WA; Rodriguez C; Mehrdad N; Nguyen DM; Ayad NG; Rai P; Capobianco AJ; Robbins DJ
Oncogene; 2017 Nov; 36(45):6306-6314. PubMed ID: 28714964
[TBL] [Abstract][Full Text] [Related]
29. Advanced MRI Findings in Medulloblastomas: Relationship to Genetic Subtypes, Histopathology, and Immunohistochemistry.
Reis J; Stahl R; Zimmermann H; Ruf V; Thon N; Kunz M; Liebig T; Forbrig R
J Neuroimaging; 2021 Mar; 31(2):306-316. PubMed ID: 33465267
[TBL] [Abstract][Full Text] [Related]
30. Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma.
Park AK; Lee JY; Cheong H; Ramaswamy V; Park SH; Kool M; Phi JH; Choi SA; Cavalli F; Taylor MD; Kim SK
BMC Cancer; 2019 Jun; 19(1):571. PubMed ID: 31185958
[TBL] [Abstract][Full Text] [Related]
31. Clinical, pathological, and molecular data on desmoplastic/nodular medulloblastoma: case studies and a review of the literature.
Siegfried A; Bertozzi AI; Bourdeaut F; Sevely A; Loukh N; Grison C; Miquel C; Lafon D; Sevenet N; Pietsch T; Dufour C; Delisle MB
Clin Neuropathol; 2016; 35(3):106-13. PubMed ID: 26857864
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic implications of CD1d expression and tumor-infiltrating macrophages in pediatric medulloblastomas.
Teo WY; Elghetany MT; Shen J; Man TK; Li X; Chintagumpala M; Su JM; Dauser R; Whitehead W; Adesina AM; Lau CC
J Neurooncol; 2014 Nov; 120(2):293-301. PubMed ID: 25115738
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of anaplasia and angiogenesis in childhood medulloblastoma: a pediatric oncology group study.
Ozer E; Sarialioglu F; Cetingoz R; Yüceer N; Cakmakci H; Ozkal S; Olgun N; Uysal K; Corapcioglu F; Canda S
Pathol Res Pract; 2004; 200(7-8):501-9. PubMed ID: 15462497
[TBL] [Abstract][Full Text] [Related]
34. Distinctive MRI features of pediatric medulloblastoma subtypes.
Yeom KW; Mobley BC; Lober RM; Andre JB; Partap S; Vogel H; Barnes PD
AJR Am J Roentgenol; 2013 Apr; 200(4):895-903. PubMed ID: 23521467
[TBL] [Abstract][Full Text] [Related]
35. Medulloblastoma, WNT-activated/SHH-activated: clinical impact of molecular analysis and histogenetic evaluation.
Cambruzzi E
Childs Nerv Syst; 2018 May; 34(5):809-815. PubMed ID: 29582169
[TBL] [Abstract][Full Text] [Related]
36. Nomograms based on preoperative multiparametric magnetic resonance imaging for prediction of molecular subgrouping in medulloblastoma: results from a radiogenomics study of 111 patients.
Dasgupta A; Gupta T; Pungavkar S; Shirsat N; Epari S; Chinnaswamy G; Mahajan A; Janu A; Moiyadi A; Kannan S; Krishnatry R; Sastri GJ; Jalali R
Neuro Oncol; 2019 Jan; 21(1):115-124. PubMed ID: 29846693
[TBL] [Abstract][Full Text] [Related]
37. Preponderance of sonic hedgehog pathway activation characterizes adult medulloblastoma.
Al-Halabi H; Nantel A; Klekner A; Guiot MC; Albrecht S; Hauser P; Garami M; Bognar L; Kavan P; Gerges N; Shirinian M; Roberge D; Muanza T; Jabado N
Acta Neuropathol; 2011 Feb; 121(2):229-39. PubMed ID: 21107850
[TBL] [Abstract][Full Text] [Related]
38. Preoperative Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio are Associated with the Prognosis of Group 3 and Group 4 Medulloblastoma.
Li K; Duan WC; Zhao HB; Wang L; Wang WW; Zhan YB; Sun T; Zhang FJ; Yu B; Bai YH; Wang YM; Ji YC; Zhou JQ; Liu XZ; Zhang ZF; Zhang ZY
Sci Rep; 2019 Sep; 9(1):13239. PubMed ID: 31519974
[TBL] [Abstract][Full Text] [Related]
39. Medulloblastoma: Distinctive Histo-Molecular Correlation with Clinical Profile, Radiologic Characteristics, and Surgical Outcome.
Narayan V; Sugur H; Jaiswal J; Arvinda HR; Arivazhagan A; Somanna S; Santosh V
Pediatr Neurosurg; 2019; 54(5):329-340. PubMed ID: 31480064
[TBL] [Abstract][Full Text] [Related]
40. mTOR pathway as a potential target in a subset of human medulloblastoma.
Pócza T; Sebestyén A; Turányi E; Krenács T; Márk A; Sticz TB; Jakab Z; Hauser P
Pathol Oncol Res; 2014 Oct; 20(4):893-900. PubMed ID: 24737380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
